CoreCap Advisors LLC Reduces Stake in AbbVie Inc. $ABBV

CoreCap Advisors LLC cut its position in shares of AbbVie Inc. (NYSE:ABBV) by 50.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,967 shares of the company’s stock after selling 21,425 shares during the quarter. CoreCap Advisors LLC’s holdings in AbbVie were worth $5,276,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Ranch Capital Advisors Inc. raised its position in shares of AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Calamos Advisors LLC raised its holdings in shares of AbbVie by 3.4% in the fourth quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock worth $106,543,000 after acquiring an additional 15,458 shares during the last quarter. Bingham Private Wealth LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at $1,147,000. Axecap Investments LLC boosted its stake in shares of AbbVie by 713.2% during the fourth quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock valued at $3,729,000 after acquiring an additional 14,313 shares during the last quarter. Finally, Legacy Edge Advisors LLC purchased a new stake in AbbVie during the 4th quarter worth about $1,265,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Up 0.9%

NYSE:ABBV opened at $245.98 on Thursday. The company has a market cap of $434.59 billion, a P/E ratio of 69.49, a P/E/G ratio of 0.81 and a beta of 0.30. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm’s 50 day moving average is $240.90 and its two-hundred day moving average is $224.61.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s dividend payout ratio is currently 195.48%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Cantor Fitzgerald boosted their target price on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research note on Monday. HSBC reiterated a “buy” rating and set a $300.00 price target on shares of AbbVie in a report on Monday, July 6th. BMO Capital Markets upped their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Guggenheim raised their target price on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Wells Fargo & Company boosted their price target on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $272.76.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund an acquisition. While the financing increases interest obligations, it provides capital to pursue a transaction intended to strengthen the company’s growth profile. AbbVie prices $9.9B senior notes to fund acquisition
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group upgraded AbbVie from “hold” to “buy,” while Cantor Fitzgerald raised its price target to $285, implying additional upside from recent trading levels. Cantor Fitzgerald boosts AbbVie price target
• Positive Sentiment: Second-quarter results exceeded expectations: revenue increased 10.2% year over year to $16.99 billion, and adjusted EPS of $3.65 surpassed the $3.61 consensus estimate. Growth in immunology and neuroscience helped offset concerns about the post-Humira transition, while third-quarter EPS guidance of $3.84–$3.88 indicates continued earnings momentum. AbbVie Q2 results and outlook
• Positive Sentiment: The FDA accepted Allergan Aesthetics’ supplemental application for BOTOX Cosmetic in masseter muscle prominence, expanding a major product into a potential new aesthetic indication. Approval could broaden BOTOX’s revenue opportunity, although the application still requires regulatory review. FDA accepts BOTOX Cosmetic application
• Positive Sentiment: Canada’s drug agency recommended conditional reimbursement of UBRELVY for acute migraine treatment, potentially improving access and supporting international growth for the newer migraine medicine. UBRELVY reimbursement recommendation
• Neutral Sentiment: RemeGen forecast a significant profit turnaround, citing stronger drug sales and an AbbVie licensing deal. The development supports AbbVie’s partnered pipeline but is unlikely to materially affect near-term results. RemeGen licensing update
• Negative Sentiment: Valuation remains a risk. Commentary noted ABBV’s trailing P/E near 70 and a model estimating fair value roughly $50 below the current level, raising concerns that much of the positive outlook may already be reflected in the stock. AbbVie year-end price prediction

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.